Rosacea
Conditions
Interventions
Doxycycline treatment group:NA
Microneedles-aided bloodletting therapy group :NA
Sponsors
Xiangya Hospital Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: (1) Females or males aged 18-55 years; (2) Patients diagnosed with rosacea based on the International Diagnostic Criteria for Rosacea(2017) ; and patients with rosacea predominantly of the erythematous capillary dilatation type based on the International Committee of Rosacea Experts(2002) typing; (3) Those who had taken oral doxycycline 0.1g 1/night for 3 months in our hospital, with unsatisfactory therapeutic effect or recurring condition, underwent microneedling treatment in our hospital 1 time/month 3 times; (4) Subjects who accept retrospective collection of clinical data and can provide portraits; (5) Understanding and willing to participate in this clinical study and voluntarily signing the informed consent form (all satisfied to be included).
Exclusion criteria
Exclusion criteria: 1) Had rosacea-related pustules; 2) Lacks of rosacea-related data (images or self-reported symptoms) before or after DXC treatment; 3) Had severe systematic diseases which could affect the outcome of this trial; 4) Pregnant of lactating women; 5) Had other facial skin disorders (e.g., psoriasis, eczema, infection); 6) Had coagulation disorders and/or bleeding tendency; 7) Underwent any treatment for rosacea in the past one month; 8) Unable/Unwilling to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinician's Erythema Assessment (CEA); | — |
Secondary
| Measure | Time frame |
|---|---|
| the Investigator's Global Assessment (IGA) scale of papule;Capillary dilatation (percentage of dilated capillary area/total facial area));Swelling ;flushing ;burning ;dryness ;itching ;Dermatology Life Quality Index (DLQI);hemorheologic ; | — |
Countries
China
Contacts
Public ContactDan Jian
Xiangya Hospital Central South University
Outcome results
None listed